Medifocus Inc. (MDFZF) 0.0324 $MDFZF
Medifocus initiates equity offering
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 8:41PM CDT
Medifocus Inc. Announces Equity Offering
Marketwire Canada - Fri Mar 27, 3:23PM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announces, subject to regulatory approval, a non-brokered private placement of up to 40,454,546 common shares (the Common Shares) at a price of $0.055 per Common Share for gross proceeds of up to $2,225,000 (the Offering). The net proceeds of the Offering will be used for general working capital. Medifocus anticipated that the Offering will be completed on or around April 2, 2015. Medifocus may pay finder's fees equal to 9% of the gross proceeds raised.
MFS.VN: 0.040 (unch)
Medifocus, Inc. Announces Financial Results for the Nine Months Ending December 31, 2014
Marketwired - Tue Mar 24, 7:00AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company) reported its financial results for the third fiscal quarter ending December 31, 2014.
MFS.VN: 0.040 (unch)
Leading 100 Medical Devices Companies of USA/Canada 2015
M2 - Mon Mar 23, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9k2tjj/usacanada) has announced the addition of the "USA/Canada Medical Devices 100: An Industry Report" report to their offering. The United States is the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016 The U.S. market value represented about 38 percent of the global medical device market in 2012. The U.S. medical device companies are highly regarded globally for their innovations and high technology products. Canada's medical device market ranks as the ninth largest in the world. Canada has an estimated around $7 billion medical device market accounting for about 2 percent of the global market. The market is projected to increase at a CAGR of 4.0% to reach US$8.3bn by 2018. Around 80% of the market is supplied by imports, principally from the USA. With this special industry report, our endeavor is to provide the new investors with a complete resourceful research report for familiarizing with the present investment trends in USA/Canadian medical devices industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical devices companies of USA/Canada - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances with foreign companies - International presence of USA/Canadian medical devices companies - R&D activities in the industry Report Includes Companies Engaged in: - Manufacturing medical equipments/devices that have life span of more than one year and that can be used repeatedly on multiple patients or multiple medical tests can be done by using them - Manufacturing medical devices providing any medical activity and/or treatment - Manufacturing diagnostic devices - Manufacturing high-tech medical instruments - Manufacturing life-support medical devices Key Features: - Financial information compiled from reliable primary and secondary sources - Business news and transactions compiled from primary news sources, company websites, and press releases - Original news source links provided for each news for further reference - Senior colleagues who analyze news have years of experience Companies Mentioned (Partial List) - Harvard Bioscience, Inc. (United States) - Hasco Medical, Incorporation (United States) - Heartware International Inc (United States) - HEI Inc (United States) - Hill-Rom Holdings, Incorporation (United States) - Hologic, Inc. (United States) - IDEXX Laboratories Inc (United States) - Illumina, Inc. (United States) - Imris Incorporation (Canada) - Inogen Inc (United States) - Insulet Corporation (United States) - Integra LifeSciences Holdings Corporation (United States) - Invacare Corporation (United States) - IRIDEX Corporation (United States) - Lifeline Scientific, Inc (United States) - Lifeloc Technologies Inc (United States) - Medifocus Inc (Canada) For more information visit http://www.researchandmarkets.com/research/9k2tjj/usacanada
IRIX: 10.15 (+0.13), ILMN: 188.16 (+1.82), HBIO: 6.59 (-0.11), PODD: 30.49 (+0.49), IART: 61.71 (+0.25), IVC: 20.21 (+0.10), IMRS: 0.88 (+0.04), INGN: 34.75 (+0.19), IDXX: 153.56 (+0.78), HRC: 50.71 (+0.30), HOLX: 33.30 (-0.10)
Medifocus, Inc. Obtains Two Newly Allowed Canadian Patents on the Prevention and Safety for the Treatment for Breast Cancer
Marketwired - Mon Dec 15, 7:30AM CST
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce it has obtained two newly allowed Canadian patents to add to its extensive intellectual properties portfolio of over 100 issued and/or pending USA and Foreign patents covering its two platform technologies for the treatments of Breast Cancer and Prostate Diseases.
MFS.VN: 0.040 (unch)
Medifocus, Inc.'s Technology Featured in a Mediaplanet Sponsored Insert in "USA Today" on Breast Cancer
Marketwire Canada - Fri Dec 05, 12:41PM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announced that its sponsored Mediaplanet insert called "Breast Cancer Care Featuring Giuliana Rancic" has been distributed in today's issue to "USA Today" newspaper subscribers and newsstands throughout the US.
MFS.VN: 0.040 (unch)
Medifocus, Inc. Launches Advertising and Marketing Campaign to Increase Shareholder Awareness of Its Breast Cancer Technology
Marketwired - Tue Nov 25, 7:02AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that it has launched an advertising and marketing campaign in the U.S. to increase shareholder awareness geared specifically towards its Adaptive Phased Array (APA) Microwave Focusing Platform, for the treatment of breast cancer. The Company has received approvals from both the USA FDA and the Canadian Bureau of Medical Devices (BMD) to initiate the Pivotal Phase III breast cancer treatment study for the Company's APA 1000 Breast Cancer System, developed from the APA Microwave Focusing Platform.
MFS.VN: 0.040 (unch)
Medifocus Inc.'s Form 20-F Registration Statement Becomes Effective Immediately
Marketwired - Wed Nov 19, 4:07PM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that its Registration Statement on Form 20-F that was filed with the U.S. Securities and Exchange Commission (the "SEC"
on September 17, 2014, as subsequently amended, has now become effective. As a result, Medifocus' common shares are now registered with the SEC pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act" .
MFS.VN: 0.040 (unch)
Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014
Marketwire Canada - Fri Nov 07, 9:56AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be broadcast on both the BNN and the Fox Business News Network by Taylor Thoen, Executive Producer of BTV-Business TV. This broadcast will be a segment of the episode that will feature Gilead Sciences, Cynapsus Therapeutics, and biOasis Technologies Inc.
GILD: 101.77 (+0.61), MFS.VN: 0.040 (unch)
Medifocus, Inc. Announces Its Sponsorship at the VM Medical 20th Anniversary Breast Cancer Conference October 23rd and 24th
Marketwired - Thu Oct 23, 7:31AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be a sponsor at the upcoming VM Medical 20th Anniversary Breast Cancer Conference held on October 23rd and 24th, 2014 in Montreal, Canada. In addition, Medifocus will present a Poster on its "Wide-Field Focused Microwave Thermotherapy in Combination with Neoadjuvant Anthracycline-based Chemotherapy to Increase Local Response for Improved Breast Conservation Potential. The Pivotal Phase III breast cancer treatment study has been approved by both the USA Food and Drug Administration and also the Canadian Bureau of Medical Devices (BMD). Dr. John R. Keyserlingk, MD, is the Principal Investigator in Canada at the VM Med (Ville Marie Medical Center) in Montreal, Canada. The USA Principal Investigational site has already been initiated at the University of Oklahoma Breast Institute under the supervision of our USA Principal Investigator, Dr. William C. Dooley, MD. The goal of the 238-patient Medifocus-sponsored randomized Phase III study is to demonstrate that preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large breast cancer tumors in the intact breast. Combining heat with chemotherapy before surgery might shrink the tumor so that it can be removed in a breast conserving surgery (lumpectomy) thus reducing the need of a mastectomy. Further details of the Medifocus, Inc. Pivotal Phase III study are published on the www.clinicaltrials.gov web site. The Medifocus, Inc. APA-1000 system used in this clinical trial is based on focused microwave thermotherapy technology exclusively licensed from the Massachusetts Institute of Technology (MIT).
MFS.VN: 0.040 (unch)
Medifocus Inc. Announces Closing of Private Placement
Marketwire Canada - Mon Sep 15, 7:44AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of a private placement of 10,281,250 Units at a price of US$0.16 per Unit for gross proceeds of US$1,645,000. Each Unit is comprised of one common share (a Common Share) and one Series D Common Share purchase warrant (a Warrant). Each Warrant entitles the holder to purchase one additional Common Share at a price of US$0.25 for a period of 36 months following the completion of the offering. If, at any time after the date that is 12 months following the Closing Date, the daily volume weighted average trading price of the Shares on the TSX Venture Exchange or the OTCQX in the United States exceeds $0.50 (or its equivalent in U.S. dollars) for at least 20 consecutive trading days, the Company may, within 30 days of such occurrence, provide an expiry acceleration notice to the holders of Series D Warrants and, if it does so, the Series D Warrants will, unless exercised, expire on the 30th day after the acceleration notice is given.
MFS.VN: 0.040 (unch)
Medifocus initiates equity offering
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 8:41PM CDT
Medifocus Inc. Announces Equity Offering
Marketwire Canada - Fri Mar 27, 3:23PM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announces, subject to regulatory approval, a non-brokered private placement of up to 40,454,546 common shares (the Common Shares) at a price of $0.055 per Common Share for gross proceeds of up to $2,225,000 (the Offering). The net proceeds of the Offering will be used for general working capital. Medifocus anticipated that the Offering will be completed on or around April 2, 2015. Medifocus may pay finder's fees equal to 9% of the gross proceeds raised.
MFS.VN: 0.040 (unch)
Medifocus, Inc. Announces Financial Results for the Nine Months Ending December 31, 2014
Marketwired - Tue Mar 24, 7:00AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company) reported its financial results for the third fiscal quarter ending December 31, 2014.
MFS.VN: 0.040 (unch)
Leading 100 Medical Devices Companies of USA/Canada 2015
M2 - Mon Mar 23, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9k2tjj/usacanada) has announced the addition of the "USA/Canada Medical Devices 100: An Industry Report" report to their offering. The United States is the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016 The U.S. market value represented about 38 percent of the global medical device market in 2012. The U.S. medical device companies are highly regarded globally for their innovations and high technology products. Canada's medical device market ranks as the ninth largest in the world. Canada has an estimated around $7 billion medical device market accounting for about 2 percent of the global market. The market is projected to increase at a CAGR of 4.0% to reach US$8.3bn by 2018. Around 80% of the market is supplied by imports, principally from the USA. With this special industry report, our endeavor is to provide the new investors with a complete resourceful research report for familiarizing with the present investment trends in USA/Canadian medical devices industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical devices companies of USA/Canada - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances with foreign companies - International presence of USA/Canadian medical devices companies - R&D activities in the industry Report Includes Companies Engaged in: - Manufacturing medical equipments/devices that have life span of more than one year and that can be used repeatedly on multiple patients or multiple medical tests can be done by using them - Manufacturing medical devices providing any medical activity and/or treatment - Manufacturing diagnostic devices - Manufacturing high-tech medical instruments - Manufacturing life-support medical devices Key Features: - Financial information compiled from reliable primary and secondary sources - Business news and transactions compiled from primary news sources, company websites, and press releases - Original news source links provided for each news for further reference - Senior colleagues who analyze news have years of experience Companies Mentioned (Partial List) - Harvard Bioscience, Inc. (United States) - Hasco Medical, Incorporation (United States) - Heartware International Inc (United States) - HEI Inc (United States) - Hill-Rom Holdings, Incorporation (United States) - Hologic, Inc. (United States) - IDEXX Laboratories Inc (United States) - Illumina, Inc. (United States) - Imris Incorporation (Canada) - Inogen Inc (United States) - Insulet Corporation (United States) - Integra LifeSciences Holdings Corporation (United States) - Invacare Corporation (United States) - IRIDEX Corporation (United States) - Lifeline Scientific, Inc (United States) - Lifeloc Technologies Inc (United States) - Medifocus Inc (Canada) For more information visit http://www.researchandmarkets.com/research/9k2tjj/usacanada
IRIX: 10.15 (+0.13), ILMN: 188.16 (+1.82), HBIO: 6.59 (-0.11), PODD: 30.49 (+0.49), IART: 61.71 (+0.25), IVC: 20.21 (+0.10), IMRS: 0.88 (+0.04), INGN: 34.75 (+0.19), IDXX: 153.56 (+0.78), HRC: 50.71 (+0.30), HOLX: 33.30 (-0.10)
Medifocus, Inc. Obtains Two Newly Allowed Canadian Patents on the Prevention and Safety for the Treatment for Breast Cancer
Marketwired - Mon Dec 15, 7:30AM CST
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce it has obtained two newly allowed Canadian patents to add to its extensive intellectual properties portfolio of over 100 issued and/or pending USA and Foreign patents covering its two platform technologies for the treatments of Breast Cancer and Prostate Diseases.
MFS.VN: 0.040 (unch)
Medifocus, Inc.'s Technology Featured in a Mediaplanet Sponsored Insert in "USA Today" on Breast Cancer
Marketwire Canada - Fri Dec 05, 12:41PM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announced that its sponsored Mediaplanet insert called "Breast Cancer Care Featuring Giuliana Rancic" has been distributed in today's issue to "USA Today" newspaper subscribers and newsstands throughout the US.
MFS.VN: 0.040 (unch)
Medifocus, Inc. Launches Advertising and Marketing Campaign to Increase Shareholder Awareness of Its Breast Cancer Technology
Marketwired - Tue Nov 25, 7:02AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that it has launched an advertising and marketing campaign in the U.S. to increase shareholder awareness geared specifically towards its Adaptive Phased Array (APA) Microwave Focusing Platform, for the treatment of breast cancer. The Company has received approvals from both the USA FDA and the Canadian Bureau of Medical Devices (BMD) to initiate the Pivotal Phase III breast cancer treatment study for the Company's APA 1000 Breast Cancer System, developed from the APA Microwave Focusing Platform.
MFS.VN: 0.040 (unch)
Medifocus Inc.'s Form 20-F Registration Statement Becomes Effective Immediately
Marketwired - Wed Nov 19, 4:07PM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that its Registration Statement on Form 20-F that was filed with the U.S. Securities and Exchange Commission (the "SEC"
on September 17, 2014, as subsequently amended, has now become effective. As a result, Medifocus' common shares are now registered with the SEC pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act" . MFS.VN: 0.040 (unch)
Medifocus to Be Broadcast on BNN and Fox Business News on November 8th and 9th, 2014
Marketwire Canada - Fri Nov 07, 9:56AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be broadcast on both the BNN and the Fox Business News Network by Taylor Thoen, Executive Producer of BTV-Business TV. This broadcast will be a segment of the episode that will feature Gilead Sciences, Cynapsus Therapeutics, and biOasis Technologies Inc.
GILD: 101.77 (+0.61), MFS.VN: 0.040 (unch)
Medifocus, Inc. Announces Its Sponsorship at the VM Medical 20th Anniversary Breast Cancer Conference October 23rd and 24th
Marketwired - Thu Oct 23, 7:31AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that it will be a sponsor at the upcoming VM Medical 20th Anniversary Breast Cancer Conference held on October 23rd and 24th, 2014 in Montreal, Canada. In addition, Medifocus will present a Poster on its "Wide-Field Focused Microwave Thermotherapy in Combination with Neoadjuvant Anthracycline-based Chemotherapy to Increase Local Response for Improved Breast Conservation Potential. The Pivotal Phase III breast cancer treatment study has been approved by both the USA Food and Drug Administration and also the Canadian Bureau of Medical Devices (BMD). Dr. John R. Keyserlingk, MD, is the Principal Investigator in Canada at the VM Med (Ville Marie Medical Center) in Montreal, Canada. The USA Principal Investigational site has already been initiated at the University of Oklahoma Breast Institute under the supervision of our USA Principal Investigator, Dr. William C. Dooley, MD. The goal of the 238-patient Medifocus-sponsored randomized Phase III study is to demonstrate that preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large breast cancer tumors in the intact breast. Combining heat with chemotherapy before surgery might shrink the tumor so that it can be removed in a breast conserving surgery (lumpectomy) thus reducing the need of a mastectomy. Further details of the Medifocus, Inc. Pivotal Phase III study are published on the www.clinicaltrials.gov web site. The Medifocus, Inc. APA-1000 system used in this clinical trial is based on focused microwave thermotherapy technology exclusively licensed from the Massachusetts Institute of Technology (MIT).
MFS.VN: 0.040 (unch)
Medifocus Inc. Announces Closing of Private Placement
Marketwire Canada - Mon Sep 15, 7:44AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of a private placement of 10,281,250 Units at a price of US$0.16 per Unit for gross proceeds of US$1,645,000. Each Unit is comprised of one common share (a Common Share) and one Series D Common Share purchase warrant (a Warrant). Each Warrant entitles the holder to purchase one additional Common Share at a price of US$0.25 for a period of 36 months following the completion of the offering. If, at any time after the date that is 12 months following the Closing Date, the daily volume weighted average trading price of the Shares on the TSX Venture Exchange or the OTCQX in the United States exceeds $0.50 (or its equivalent in U.S. dollars) for at least 20 consecutive trading days, the Company may, within 30 days of such occurrence, provide an expiry acceleration notice to the holders of Series D Warrants and, if it does so, the Series D Warrants will, unless exercised, expire on the 30th day after the acceleration notice is given.
MFS.VN: 0.040 (unch)
